Compare L3Harris Technologies Inc (LHX) vs 10X Genomics Inc (TXG) Price & Performance

LHX trades at $280.57, down 0.51% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains robust cash flow. Recent contracts include a U.S. Space Force satellite deal and U.S. Army radio orders, supporting growth. Valuation metrics show a P/E of 30.62 and P/S of 2.36, with revenue rising to $21.87B in 2025.

Outlook is positive with a consensus price target of $367.50, implying 31% upside, driven by defense spending and execution. Risks include debt levels and geopolitical volatility. Analysts are 75% buy-rated, but technical indicators suggest near-term caution amid bearish moving averages.

TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.

The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.